Loading...
OTCMDTRK
Market cap263kUSD
Dec 17, Last price  
0.10USD
Name

DATATRAK International Inc

Chart & Performance

D1W1MN
OTCM:DTRK chart
P/E
0.10
P/S
0.04
EPS
1.01
Div Yield, %
0.00%
Shrs. gr., 5y
19.42%
Rev. gr., 5y
-3.65%
Revenues
6m
+4.37%
2,245,6314,720,9127,052,15811,305,11215,734,74517,690,33610,561,8688,826,0609,716,22510,900,71111,010,7929,959,7048,982,8677,524,0437,447,3567,742,5697,157,0096,381,5435,925,3946,184,265
Net income
3m
P
-7,354,233-6,390,610-1,048,621817,0342,538,347-4,490,410-10,853,503-16,796,605-1,550,026-138,382-1,306,852-2,898,8701,016,793219,696161,575386,799-90,186-249,883-888,5672,657,418
CFO
4m
P
-6,295,191-5,281,984-125,369-63,2031,717,078658,976-4,776,240-5,321,3471,082,872466,0921,011,478-1,389,8411,238,421157,996460,3152,423,419-1,352,141286,219-2,745,2693,718,451

Profile

DATATRAK International, Inc., a technology and services company, provides unified clinical solutions and related services for the clinical trials industry. The company offers DATATRAK ONE Unified Experience, a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Its products include UX CTMS 360 for planning and managing trials; UX Trial to streamline design-to-deployment process using a tool; UX EDC & Medical Coding for capturing and delivering data; UX Randomization and Trial Supply Management to randomize patients and automate supply; UX Patient Data Capture; UX Safety; and UX Training to train users and track certificates. The company also provides DATATRAK Clinical Consulting Services, such as training, support, learning center, Software as a Service hosting, standards, and trial design services. It serves contract research organizations, pharma and biotech companies, and clinical trial device companies. DATATRAK International, Inc. was founded in 1991 and is headquartered in Mayfield Heights, Ohio.
URL
https://www.datatrak.com/
IPO date
Jun 11, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,184
4.37%
5,925
-7.15%
6,382
-10.84%
Cost of revenue
1,037
2,250
3,192
Unusual Expense (Income)
NOPBT
5,147
3,675
3,189
NOPBT Margin
83.23%
62.03%
49.97%
Operating Taxes
56
(3)
2
Tax Rate
0.00%
0.00%
NOPAT
5,147
3,675
3,189
Net income
2,657
-399.07%
(889)
255.59%
(250)
177.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
7
24
BB yield
-0.58%
-0.11%
Debt
Debt current
267
750
35
Long-term debt
1,041
Deferred revenue
3,429
948
1,121
Other long-term liabilities
732
1,191
Net debt
100
(10)
(878)
Cash flow
Cash from operating activities
3,718
(2,745)
286
CAPEX
(333)
(8,507)
(753)
Cash from investing activities
(80)
156
(1,301)
Cash from financing activities
(483)
722
43
FCF
7,351
3,799
3,310
Balance
Cash
167
636
1,701
Long term investments
123
254
Excess cash
463
1,635
Stockholders' equity
4,090
269
1,280
Invested Capital
1,838
3,476
2,251
ROIC
193.75%
128.35%
137.41%
ROCE
280.09%
99.12%
90.31%
EV
Common stock shares outstanding
5,670
2,814
2,418
Price
0.04
-90.00%
0.40
-95.51%
8.90
50.85%
Market cap
227
-79.85%
1,126
-94.77%
21,518
52.87%
EV
327
1,116
20,639
EBITDA
5,214
3,489
4,063
EV/EBITDA
0.06
0.32
5.08
Interest
37
2
Interest/NOPBT
1.01%
0.06%